Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy

Modern Rheumatology

Volumn 23, Issue 6, 2013, Pages 1094-1100

  Watanabe, Ryu ^a   Ishii, Tomonori ^a   Nakamura, Kyohei ^a   Shirai, Tsuyoshi ^a   Tajima, Yumi ^a   Fujii, Hiroshi ^a   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis B virus; Immunosuppressive therapy; Resolved HBV carrier; Systemic lupus erythematosus

Indexed keywords

ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREVALENCE;

EID: 84894359996     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0797-4     Document Type: Article

References (22)

1. Lee WM, Hepatitis B. Virus infection. N Engl J Med. 1997;337: 1733-45.
2. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15: 1356-61.
3. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004;350: 1118-29.
4. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52-6.
5. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21: 16-23.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum. 1997;40:1725.
7. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353: 2550-8.
8. Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-a blocker in the treatment of rhematic diseases. J Rheumatol. 2010;37: 346-50.
9. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40: 1072-7.
10. Demir M, Serin E, Gokturk S, Ozturk NA, Kulaksizoglu S, Yulmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol. 2008;20: 668-73.
11. Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010;10: 1389-93.
12. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37: 1172-9.
13. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21: 621-7.
14. Chng HH, Fock KM, Chew CN, Guan R, Feng PH, Boey ML, et al. Hepatitis B virus infection in patients with systemic lupus erythematosus. Singapore Med J. 1993;34: 325-6.
15. Lu CL, Tsai ST, Chan CY, Hwang SJ, Tsai CY, Wu JC, et al. Hepatitis B infection and changes in interferon-alpha and - gamma production in patients with systemic lupus erythematosus in Taiwan. J Gastroenterol Hepatol. 1997;12: 272-6.
16. Abu-Shakra M, EI-Sana S, Margalith M, Sikuler E, Neumann L, Buskila D. Hepatitis B and C viruses serology in patients with SLE. Lupus. 1997;6: 543-4.
17. Bonafede RP, van Staden M, Klemp P. Hepatitis B virus infection and liver function in patients with systemic lupus erythematosus. J Rheumatol. 1986;13: 1050-2.
18. Permin H, Aldershvile J, Nielsen J. Hepatitis B virus infection in patients with rheumatic diseases. Ann Rheum Dis. 1982;41: 479-82.
19. Ram M, Anaya JM, Barzilai O, Izhaky D, Katz BP, Blank M, et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev. 2008;7: 621-5.
20. Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthr Res Ther. 2009;11:R179.
21. Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-a inhibitors. Hepatol Res. 2012;42: 333-9.
22. Wands JR, Chuna CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68: 105-12.